Q-Line Biotech Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹95(27.70%)
Premium (ELP)
Q-Line Biotech Limited's successfully transitioned to public market status with its listing on NSE on May 29, 2026. The IPO mobilized 62,53,200 Shares in cumulative capital, including 62,53,200 Shares for corporate expansion.
The public offering was conducted within the price parameters of ₹326 to ₹343, with minimum investment lots of 400 shares. subscription activity between May 21, 2026 and May 25, 2026 demonstrated market reception to the company's valuation and growth narrative.
The allotment process concluded on May 26, 2026, finalizing share distribution to successful bidders. The listing represents a transformational event, providing the company with enhanced market visibility, regulatory compliance framework, and access to diversified investor capital.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Q-Line Biotech Limited is a healthcare diagnostics company engaged in the manufacturing and supply of In-Vitro Diagnostic (IVD) products, pathology reagents, rapid test kits, and laboratory equipment for hospitals, diagnostic laboratories, and healthcare institutions across India. Established in 2010, the company focuses on affordable diagnostic solutions and operates in the medical diagnostics and healthcare consumables segment, with its proposed IPO planned for listing on the NSE EMERGE SME platform.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Strong Manufacturing & R&D Capabilities : Focus on reverse engineering, innovation, and quality control supports product development.
- Diversified Diagnostic Product Portfolio : Wide range of reagents, kits, POC devices, and diagnostic equipment reduces dependency on one segment.
- Wide Distribution Network : Presence across all four regions in India ensures strong market reach and customer access.
- Regulatory Compliance Risk : Diagnostic and healthcare products are subject to strict approvals and quality standards.
- Dependence on Healthcare Sector Spending : Revenue linked to hospital, lab, and diagnostic industry demand.
- High Competition in IVD Market : Faces competition from established domestic and global diagnostic companies.
- Saurabh Garg
- Amita Garg
- Ayush Garg
- Ajay Kumar Mahanty
- Abhay Agrawal
Q-Line Biotech Limited
Purva Sharegistry India Private Limited